Blanca Herrero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Blanca Herrero has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Pérez-Martínez
Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain
2 shared publications - Marta González-Vicent
Stem Cell Transplant Unit, Niño Jesús Hospital, Madrid, Spain
2 shared publications Alberto Martín-Vega
CSUR, Seville, Spain
1 shared publication- Alfredo Tagarro
Fundación de Investigación Biomédica Hospital 12 de Octubre, Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain
1 shared publication Alvaro Ballesteros
Fundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain
1 shared publication- Alvaro Lassaletta
Hospital Infantil Universitario Niño Jesús
1 shared publication
Latest Publications
- Open Access
- 31 May 2024
- Published by Elsevier in Journal of Pediatric Surgery Open
- Vol. 8
Non-Wilms renal tumors: Twenty years experience in a referral center
- 31 May 2024
- Published by Elsevier in Journal of Pediatric Surgery Open
- Vol. 8
Open AccessNon-Wilms renal tumors: Twenty years experience in a referral center
- 30 September 2021
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 17 (6) , 609-618
Comparison of clinical outcomes between unrelated single umbilical cord blood and “ex-vivo” T-cell depleted haploidentical transplantation in children with hematological malignancies
Background Over the last two decades, umbilical cord blood (UCB) and haploidentical transplantation (HaploHSCT) have emerged as alternative sources of hematopoietic stem cell for allogeneic transplantation. There are few retrospective studies and no prospective studies comparing both types of alternative transplantation in pediatric patients. Results We analyzed the data of 134 children with hematological malignancies who received a hematopoietic stem cell transplantation from a single umbilical cord blood (UCB) (n = 42) or an “ex-vivo” T-cell depleted transplant from a haploidentical-related donor (HaploHSCT) (n = 92) between 1996 and 2014. Hematological recovery was faster after HaploHSCT than the UCB transplant group (median times to neutrophil and platelet recovery: 13 vs. 16 days, 10 vs. 57 days, respectively) (P < 0.001). The HaploHSCT group had a significantly early immune reconstitution based on NK and CD8 + T cells compared with the UCB group. However, after the first year post-transplantation, HaploHSCT had a lower number of CD4 + T and B lymphocytes compared with the UCB transplant recipients. The cumulative incidence of TRM was 29±8% in the HaploHSCT group versus 40±5% in the UCB group. Relapse incidence was 21±7% in the HaploHSCT group and 19±8% in the UCB group. Probability of DFS was 58±8% in the HaploHSCT group versus 40±9% in the UCB group (P = 0.051). Conclusions TCD haploidentical transplant is associated with advantages in terms of engraftment and early immune reconstitution kinetics. TCD haploidentical transplant was associated with lower incidence of infectious and non-infectious complications, especially in the early phases of the transplant compared with UCB transplant recipients. However, there are no advantages in transplant outcomes compared with UCB transplant.
- 30 September 2021
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 17 (6) , 609-618
Comparison of clinical outcomes between unrelated single umbilical cord blood and “ex-vivo” T-cell depleted haploidentical transplantation in children with hematological malignancies
Background Over the last two decades, umbilical cord blood (UCB) and haploidentical transplantation (HaploHSCT) have emerged as alternative sources of hematopoietic stem cell for allogeneic transplantation. There are few retrospective studies and no prospective studies comparing both types of alternative transplantation in pediatric patients. Results We analyzed the data of 134 children with hematological malignancies who received a hematopoietic stem cell transplantation from a single umbilical cord blood (UCB) (n = 42) or an “ex-vivo” T-cell depleted transplant from a haploidentical-related donor (HaploHSCT) (n = 92) between 1996 and 2014. Hematological recovery was faster after HaploHSCT than the UCB transplant group (median times to neutrophil and platelet recovery: 13 vs. 16 days, 10 vs. 57 days, respectively) (P < 0.001). The HaploHSCT group had a significantly early immune reconstitution based on NK and CD8 + T cells compared with the UCB group. However, after the first year post-transplantation, HaploHSCT had a lower number of CD4 + T and B lymphocytes compared with the UCB transplant recipients. The cumulative incidence of TRM was 29±8% in the HaploHSCT group versus 40±5% in the UCB group. Relapse incidence was 21±7% in the HaploHSCT group and 19±8% in the UCB group. Probability of DFS was 58±8% in the HaploHSCT group versus 40±9% in the UCB group (P = 0.051). Conclusions TCD haploidentical transplant is associated with advantages in terms of engraftment and early immune reconstitution kinetics. TCD haploidentical transplant was associated with lower incidence of infectious and non-infectious complications, especially in the early phases of the transplant compared with UCB transplant recipients. However, there are no advantages in transplant outcomes compared with UCB transplant.
- 25 September 2021
- Published by Elsevier in The Journal of Pediatrics
- Vol. 241, 126-132.e3
Dynamics of Reverse Transcription-Polymerase Chain Reaction and Serologic Test Results in Children with SARS-CoV-2 Infection
- 25 September 2021
- Published by Elsevier in The Journal of Pediatrics
- Vol. 241, 126-132.e3
Dynamics of Reverse Transcription-Polymerase Chain Reaction and Serologic Test Results in Children with SARS-CoV-2 Infection
- 1 March 2014
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 36 (2) , e109-e114
Cunninghamella bertholletiae Infection in Children
Mucormycosis is an emerging fungal infection affecting mainly immunosuppressed hosts. Cunninghamella bertholletiae causes the highest mortality among all mucormycetes. Infection by C. bertholletiae has rarely been reported in children. We present 2 children with acute leukemia and disseminated infection by C. bertholletiae, and review the relevant literature.
- 1 March 2014
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 36 (2) , e109-e114
Cunninghamella bertholletiae Infection in Children
Mucormycosis is an emerging fungal infection affecting mainly immunosuppressed hosts. Cunninghamella bertholletiae causes the highest mortality among all mucormycetes. Infection by C. bertholletiae has rarely been reported in children. We present 2 children with acute leukemia and disseminated infection by C. bertholletiae, and review the relevant literature.